vs
COHEN & STEERS, INC.（CNS）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是COHEN & STEERS, INC.的1.4倍（$207.3M vs $143.8M），COHEN & STEERS, INC.净利率更高（24.3% vs -62.0%，领先86.3%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 2.9%），Ultragenyx Pharmaceutical Inc.自由现金流更多（$-100.8M vs $-126.4M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 8.3%）
科恩斯蒂尔是一家美国投资管理企业，专注于通过房地产投资信托（REIT）开展不动产证券投资，同时布局优先证券相关的另类收益类投资业务，在全球不动产和另类收益投资领域拥有专业的运营经验。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CNS vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $143.8M | $207.3M |
| 净利润 | $34.9M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 28.0% | -54.7% |
| 净利率 | 24.3% | -62.0% |
| 营收同比 | 2.9% | 25.9% |
| 净利润同比 | -23.9% | 3.5% |
| 每股收益（稀释后） | $0.67 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $143.8M | $207.3M | ||
| Q3 25 | $141.7M | $159.9M | ||
| Q2 25 | $136.1M | $166.5M | ||
| Q1 25 | $134.5M | $139.3M | ||
| Q4 24 | $139.8M | $164.6M | ||
| Q3 24 | $133.2M | $139.5M | ||
| Q2 24 | $121.7M | $147.0M | ||
| Q1 24 | $122.7M | $108.8M |
| Q4 25 | $34.9M | $-128.6M | ||
| Q3 25 | $41.7M | $-180.4M | ||
| Q2 25 | $36.8M | $-115.0M | ||
| Q1 25 | $39.8M | $-151.1M | ||
| Q4 24 | $45.8M | $-133.2M | ||
| Q3 24 | $39.7M | $-133.5M | ||
| Q2 24 | $31.8M | $-131.6M | ||
| Q1 24 | $34.0M | $-170.7M |
| Q4 25 | 28.0% | -54.7% | ||
| Q3 25 | 34.5% | -106.9% | ||
| Q2 25 | 31.8% | -64.8% | ||
| Q1 25 | 33.6% | -102.6% | ||
| Q4 24 | 35.3% | -74.3% | ||
| Q3 24 | 33.7% | -94.6% | ||
| Q2 24 | 31.5% | -79.1% | ||
| Q1 24 | 32.8% | -151.9% |
| Q4 25 | 24.3% | -62.0% | ||
| Q3 25 | 29.4% | -112.8% | ||
| Q2 25 | 27.1% | -69.0% | ||
| Q1 25 | 29.6% | -108.5% | ||
| Q4 24 | 32.8% | -80.9% | ||
| Q3 24 | 29.8% | -95.7% | ||
| Q2 24 | 26.1% | -89.5% | ||
| Q1 24 | 27.7% | -156.8% |
| Q4 25 | $0.67 | $-1.28 | ||
| Q3 25 | $0.81 | $-1.81 | ||
| Q2 25 | $0.72 | $-1.17 | ||
| Q1 25 | $0.77 | $-1.57 | ||
| Q4 24 | $0.89 | $-1.34 | ||
| Q3 24 | $0.77 | $-1.40 | ||
| Q2 24 | $0.63 | $-1.52 | ||
| Q1 24 | $0.68 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $145.5M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $562.0M | $-80.0M |
| 总资产 | $876.7M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $145.5M | $421.0M | ||
| Q3 25 | $98.1M | $202.5M | ||
| Q2 25 | $95.4M | $176.3M | ||
| Q1 25 | $65.2M | $127.1M | ||
| Q4 24 | $183.0M | $174.0M | ||
| Q3 24 | $106.5M | $150.6M | ||
| Q2 24 | $122.0M | $480.7M | ||
| Q1 24 | $99.5M | $112.3M |
| Q4 25 | $562.0M | $-80.0M | ||
| Q3 25 | $550.3M | $9.2M | ||
| Q2 25 | $528.5M | $151.3M | ||
| Q1 25 | $507.7M | $144.2M | ||
| Q4 24 | $511.7M | $255.0M | ||
| Q3 24 | $491.0M | $346.8M | ||
| Q2 24 | $463.2M | $432.4M | ||
| Q1 24 | $378.9M | $140.3M |
| Q4 25 | $876.7M | $1.5B | ||
| Q3 25 | $801.6M | $1.2B | ||
| Q2 25 | $751.0M | $1.3B | ||
| Q1 25 | $834.9M | $1.3B | ||
| Q4 24 | $812.4M | $1.5B | ||
| Q3 24 | $727.8M | $1.5B | ||
| Q2 24 | $784.1M | $1.6B | ||
| Q1 24 | $680.7M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-120.4M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-126.4M | $-100.8M |
| 自由现金流率自由现金流/营收 | -87.9% | -48.6% |
| 资本支出强度资本支出/营收 | 4.2% | 0.5% |
| 现金转化率经营现金流/净利润 | -3.45× | — |
| 过去12个月自由现金流最近4个季度 | $-253.6M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $-120.4M | $-99.8M | ||
| Q3 25 | $55.1M | $-91.4M | ||
| Q2 25 | $-67.6M | $-108.3M | ||
| Q1 25 | $-108.9M | $-166.5M | ||
| Q4 24 | $96.7M | $-79.3M | ||
| Q3 24 | $25.6M | $-67.0M | ||
| Q2 24 | $31.4M | $-77.0M | ||
| Q1 24 | $4.9M | $-190.7M |
| Q4 25 | $-126.4M | $-100.8M | ||
| Q3 25 | $52.6M | $-92.7M | ||
| Q2 25 | $-69.8M | $-110.7M | ||
| Q1 25 | $-110.0M | $-167.8M | ||
| Q4 24 | $85.0M | $-79.5M | ||
| Q3 24 | $24.2M | $-68.6M | ||
| Q2 24 | $27.1M | $-79.0M | ||
| Q1 24 | $537.0K | $-193.9M |
| Q4 25 | -87.9% | -48.6% | ||
| Q3 25 | 37.1% | -58.0% | ||
| Q2 25 | -51.3% | -66.5% | ||
| Q1 25 | -81.8% | -120.5% | ||
| Q4 24 | 60.8% | -48.3% | ||
| Q3 24 | 18.2% | -49.2% | ||
| Q2 24 | 22.3% | -53.7% | ||
| Q1 24 | 0.4% | -178.2% |
| Q4 25 | 4.2% | 0.5% | ||
| Q3 25 | 1.8% | 0.8% | ||
| Q2 25 | 1.6% | 1.5% | ||
| Q1 25 | 0.8% | 1.0% | ||
| Q4 24 | 8.3% | 0.1% | ||
| Q3 24 | 1.1% | 1.2% | ||
| Q2 24 | 3.5% | 1.4% | ||
| Q1 24 | 3.5% | 3.0% |
| Q4 25 | -3.45× | — | ||
| Q3 25 | 1.32× | — | ||
| Q2 25 | -1.84× | — | ||
| Q1 25 | -2.74× | — | ||
| Q4 24 | 2.11× | — | ||
| Q3 24 | 0.65× | — | ||
| Q2 24 | 0.99× | — | ||
| Q1 24 | 0.14× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CNS
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
